Tue, June 21, 2022
Sun, June 19, 2022
Fri, June 17, 2022
Thu, June 16, 2022
Wed, June 15, 2022
Tue, June 14, 2022
Mon, June 13, 2022
Sun, June 12, 2022
Fri, June 10, 2022
Thu, June 9, 2022
Wed, June 8, 2022

Michael Ulz Maintained (BPMC) at Hold with Decreased Target to $65 on, Jun 14th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-65-on-jun-14th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Michael Ulz of Morgan Stanley, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Decreased Target from $92 to $65 on, Jun 14th, 2022.

Michael has made no other calls on BPMC in the last 4 months.



There are 6 other peers that have a rating on BPMC. Out of the 6 peers that are also analyzing BPMC, 2 agree with Michael's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Andrew Berens of "SVB Leerink" Maintained at Hold with Decreased Target to $60 on, Monday, June 13th, 2022
  • Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $65 on, Thursday, May 19th, 2022


These are the ratings of the 4 analyists that currently disagree with Michael


  • David Lebowitz of "Citigroup" Downgraded from Hold to Strong Sell and Decreased Target to $41 on, Friday, June 10th, 2022
  • Eun Yang of "Jefferies" Upgraded from Hold to Strong Buy and Decreased Target to $78 on, Wednesday, June 1st, 2022
  • Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $105 on, Friday, March 4th, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $100 on, Thursday, February 17th, 2022

Publication Contributing Sources